<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03716700</url>
  </required_header>
  <id_info>
    <org_study_id>SHP664-402</org_study_id>
    <nct_id>NCT03716700</nct_id>
  </id_info>
  <brief_title>Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)</brief_title>
  <official_title>Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxalta Innovations GmbH, now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide insights on the infusion parameters, dosing, and experience of&#xD;
      participants transitioning to CUVITRU in a real-world setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Actual">July 23, 2020</completion_date>
  <primary_completion_date type="Actual">July 23, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Infusion parameter 1: Cohort 1-Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median infusion volume per site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 1: Cohort 1- Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Median infusion volume per site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 1: Cohort 1- Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Median infusion volume per site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 1: Cohort 1- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median infusion volume per site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 1: Cohort 2- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median infusion volume per site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 1: Cohort 2- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median infusion volume per site</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 1.1: Cohort 1- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median infusion volume per infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 1.1: Cohort 1- Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Median infusion volume per infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 1.1: Cohort 1- Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Median infusion volume per infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 1.1: Cohort 1- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median infusion volume per infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 1.1: Cohort 2- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median infusion volume per infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 1.1: Cohort 2- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median infusion volume per infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 2: Cohort 1- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median number of infusion sites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 2: Cohort 1- Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Median number of infusion sites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 2: Cohort 1- Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Median number of infusion sites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 2: Cohort 1- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusion sites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 2: Cohort 2- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median number of infusion sites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 2: Cohort 2- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusion sites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3: Cohort 1- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median infusion duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3: Cohort 1- Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Median infusion duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3: Cohort 1- Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Median infusion duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3: Cohort 1- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median infusion duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3: Cohort 2- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median infusion duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3: Cohort 2- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median infusion duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.1: Cohort 1- Month 3 Follow-up</measure>
    <time_frame>Month 3</time_frame>
    <description>Median number of infusions to reach participant's maximum infusion volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.1: Cohort 1- Month 6 Follow-up</measure>
    <time_frame>Month 6</time_frame>
    <description>Median number of infusions to reach participant's maximum infusion volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.1: Cohort 1- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusions to reach participant's maximum infusion volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.1: Cohort 2- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusions to reach participant's maximum infusion volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.2: Cohort 1- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median number of infusions per month per participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.2: Cohort 1- Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Median number of infusions per month per participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.2: Cohort 1- Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Median number of infusions per month per participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.2: Cohort 1- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusions per month per participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.2: Cohort 2- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median number of infusions per month per participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.2: Cohort 2- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusions per month per participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.3: Cohort 1- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median number of infusions to reach final dose interval per participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.3: Cohort 1- Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Median number of infusions to reach final dose interval per participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.3: Cohort 1- Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Median number of infusions to reach final dose interval per participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.3: Cohort 1- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusions to reach final dose interval per participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.3: Cohort 2- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median number of infusions to reach final dose interval per participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.3: Cohort 2- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusions to reach final dose interval per participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 1: Cohort 3- 12 Month Final Follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median infusion volume per site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 1.1: Cohort 3- 12 Month Final Follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median infusion volume per infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 2: Cohort 3- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusion sites.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3: Cohort 3- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median infusion duration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.1: Cohort 3- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusions to reach participant's maximum infusion volume (infusion rate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.2: Cohort 3- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusions per month per participant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infusion parameter 3.3: Cohort 3- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusions to reach final dose interval per participant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.1: Cohort 1- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median maximal infusion rate per site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.1: Cohort 1- Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Median maximal infusion rate per site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.1: Cohort 1- Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Median maximal infusion rate per site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.1: Cohort 1- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median maximal infusion rate per site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.1: Cohort 2- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Median maximal infusion rate per site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.1: Cohort 2- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median maximal infusion rate per site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.2: Cohort 1- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of infusions that are discontinued, slowed, or interrupted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.2: Cohort 1- Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Number of infusions that are discontinued, slowed, or interrupted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.2: Cohort 1- Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of infusions that are discontinued, slowed, or interrupted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.2: Cohort 1- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Number of infusions that are discontinued, slowed, or interrupted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.2: Cohort 2- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Number of infusions that are discontinued, slowed, or interrupted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.2: Cohort 2- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Number of infusions that are discontinued, slowed, or interrupted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.3: Cohort 1- Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Median number of infusions to reach participant's maximum infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.3: Cohort 1- Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Median number of infusions to reach participant's maximum infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.3: Cohort 1- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusions to reach participant's maximum infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.3: Cohort 2- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusions to reach participant's maximum infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.1: Cohort 1- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.1: Cohort 1- Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Mean dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.1: Cohort 1- Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Mean dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.1: Cohort 1- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Mean dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.1: Cohort 2- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.1: Cohort 2- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Mean dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.2: Cohort 1- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.2: Cohort 1- Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Mean dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.2: Cohort 1- Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Mean dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.2: Cohort 1- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Mean dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.2: Cohort 2- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.2: Cohort 2- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Mean dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.3: Cohort 1- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean number of dose adjustments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.3: Cohort 1- Month 3</measure>
    <time_frame>Month 3</time_frame>
    <description>Mean number of dose adjustments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.3: Cohort 1- Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Mean number of dose adjustments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.3: Cohort 1- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Mean number of dose adjustments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.3: Cohort 2- Start of data collection</measure>
    <time_frame>Baseline</time_frame>
    <description>Mean number of dose adjustments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.3: Cohort 2- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Mean number of dose adjustments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.1: Cohort 3- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median maximal infusion rate per site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.2: Cohort 3- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Number of infusions that are discontinued, slowed, or interrupted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 4.3: Cohort 3- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Median number of infusions to reach participant's maximum infusion rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.1: Cohort 3- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Mean dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.2: Cohort 3- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Mean dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion parameter 5.3: Cohort 3- 12 Month final follow-up</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>Mean number of dose adjustments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9): Cohort 1</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness (3 items), convenience (3 items), and global satisfaction (3 items). Scores for each domain are calculated by adding up the items in each domain and then transforming the composite score into a value ranging from 0 to 100. Higher score indicated greater satisfaction in that domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9): Cohort 2</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness (3 items), convenience (3 items), and global satisfaction (3 items). Scores for each domain are calculated by adding up the items in each domain and then transforming the composite score into a value ranging from 0 to 100. Higher score indicated greater satisfaction in that domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9): Cohort 3</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>TSQM-9 is a 9-item, validated, self-administered instrument used to assess participant's satisfaction with medication. The three domains assessed are effectiveness (3 items), convenience (3 items), and global satisfaction (3 items). Scores for each domain are calculated by adding up the items in each domain and then transforming the composite score into a value ranging from 0 to 100. Higher score indicated greater satisfaction in that domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality Index (LQI): Cohort 1</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>The LQI is a self-administered questionnaire developed specifically for participants/legal guardians involved in IVIG treatments. It consists of 15-items, divided into four domains: treatment interferences (6 items), therapy-related problems (4 items), therapy setting (3 items), and treatment costs (2 items). Items are rated on a 7-point Likert-type scale ranging from 1: &quot;Extremely bad&quot; to 7: &quot;Extremely good&quot;. Total scores range from 15 to 105, with higher scores indicating the highest possible satisfaction with factors such as independence, therapy convenience, social/school/work activities, and health and travel costs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality Index (LQI): Cohort 2</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>The LQI is a self-administered questionnaire developed specifically for participants/legal guardians involved in IVIG treatments. It consists of 15-items, divided into four domains: treatment interferences (6 items), therapy-related problems (4 items), therapy setting (3 items), and treatment costs (2 items). Items are rated on a 7-point Likert-type scale ranging from 1: &quot;Extremely bad&quot; to 7: &quot;Extremely good&quot;. Total scores range from 15 to 105, with higher scores indicating the highest possible satisfaction with factors such as independence, therapy convenience, social/school/work activities, and health and travel costs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality Index (LQI): Cohort 3</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>The LQI is a self-administered questionnaire developed specifically for participants/legal guardians involved in IVIG treatments. It consists of 15-items, divided into four domains: treatment interferences (6 items), therapy-related problems (4 items), therapy setting (3 items), and treatment costs (2 items). Items are rated on a 7-point Likert-type scale ranging from 1: &quot;Extremely bad&quot; to 7: &quot;Extremely good&quot;. Total scores range from 15 to 105, with higher scores indicating the highest possible satisfaction with factors such as independence, therapy convenience, social/school/work activities, and health and travel costs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Preference Questionnaire (TPQ): Cohort 1</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>The TPQ is a self-administered questionnaire developed to assess participants' preference towards the administration of new subcutaneous immunoglobulin G (SCIG) therapy.&#xD;
There are 4-items on the questionnaire, which investigate a participant's reference on the clinic/hospital/home setting of receiving the immunoglobulin therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the SCIG treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Preference Questionnaire (TPQ): Cohort 2</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>The TPQ is a self-administered questionnaire developed to assess participants' preference towards the administration of new subcutaneous immunoglobulin G (SCIG) therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the SCIG treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Preference Questionnaire (TPQ): Cohort 3</measure>
    <time_frame>12 Month final follow-up</time_frame>
    <description>The TPQ is a self-administered questionnaire developed to assess participants' preference towards the administration of new subcutaneous immunoglobulin G (SCIG) therapy. There are 4-items on the questionnaire, which investigate a participant's preference on the clinic/hospital/home setting of receiving the immunoglobulin therapy, the participant's rating on the frequency and method of administration, and the participant's preference to continue receiving the SCIG treatment.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">126</enrollment>
  <condition>Primary Immunodeficiency Diseases (PID)</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Cohort1 will include the participants who have been transitioned to CUVITRU at the time of enrollment in the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Cohort 2 will include participants 6 months (±2 weeks) after CUVITRU initiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <description>Cohort 3 will include participants 12 months (-1 or +2 months) after CUVITRU initiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CUVITRU</intervention_name>
    <description>CUVITRU</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>20% Solution</other_name>
    <other_name>IGSC</other_name>
    <other_name>Immune Globulin Subcutaneous (Human)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Data will be collected on approximately 500 participants with primary immunodeficiency&#xD;
        (PID) and secondary immunodeficiency (SID) requiring Immunoglobulin G (IgG) replacement&#xD;
        therapy across 8-10 sites in Canada (excluding Quebec). Any specific number of participants&#xD;
        in each cohort is not a requirement.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (The participant will not be considered eligible for the study without&#xD;
        meeting all of the criteria below):&#xD;
&#xD;
          -  Voluntarily provide written, signed, and dated (personally or via a legally authorized&#xD;
             representative) informed consent or assent as applicable to participate in the study;&#xD;
&#xD;
          -  Participant &gt; 2 years of age with a documented diagnosis of PID or SID requiring IgG&#xD;
             replacement therapy, as defined by the International Union of Immunological Societies&#xD;
             Scientific Committee 2009 and by diagnostic criteria according to Conley et al., 1999;&#xD;
&#xD;
          -  Participant has received subcutaneous immunoglobulin (SCIG) therapy previous to&#xD;
             CUVITRU for at least 3 months; and&#xD;
&#xD;
          -  Participant has received CUVITRU in line with the product specification (CUVITRU&#xD;
             Product Monograph (Baxalta Canada Corporation, 2018) at start of study&#xD;
&#xD;
        Exclusion Criteria (Participants are excluded from the study if any of the following&#xD;
        criteria are met):&#xD;
&#xD;
          -  Participation in any interventional clinical study within the last 30 days&#xD;
&#xD;
          -  Participant participates in a clinical study in parallel during the observation&#xD;
             period; and&#xD;
&#xD;
          -  Participant had a dose change 30 days prior to transition to CUVITRU for Cohort 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of McMaster</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand River Allergy</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 5E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Allergists</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/5f6b5fe84db2bf003ab47afc</url>
    <description>To obtain more information on the study, click here/on this link</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

